RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ZAMAGNI C
Collezione AOU Città della Salute di Torino

Items : 6

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2.

2024
AO Ordine Mauriziano
AOU Città della Salute di Torino

Barretina Ginesta MP; Uggeri S; Rulli E; Laudani ME; Lissoni AA; Petrella M; Tognon G; Ferrero A; Manso L; Takehara K; Tasca G; Zamagni C; McQueen J; Nakagawa S; Piovano E; Pardo B; Lee YC; Nishio S; Allan K; Fariñas-Madrid L; Parma G; Marth C; Marmé F; Rabaglio M; Antill Y; Choi CH; Hudson E; Galli F; Harano K; et alii...

MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study. in Cancers / Cancers (Basel). 2023 Dec 20;16(1):41. doi: 10.3390/cancers16010041.

2023
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tuninetti V; Picardo E; Vertechy L; Bergamini A; Palaia I; Artioli G; Parisi A; Scandurra G; Scollo P; Baldoni A; Malaguti P; Cassani C; Zamagni C; Pisano C; Ricotti A; Marchetti C; Turinetto M; Scotto G; Scambia G; Pignata S; Valabrega G;

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. in British journal of cancer / Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9.

2023
AOU Città della Salute di Torino
ASL Vercelli

Aglietta M; Arcangeli V; Benedetti Panici P; De Giorgi U; Zola P; Rubio-Pérez MJ; DeCensi A; Tognon G; Pardo B; Romeo M; Tasca G; Funari G; Iglesias M; Biagioli E; Mirza MR; Deryal M; Fossati R; Barretina-Ginesta MP; Herbertson R; Riniker S; Nyvang GB; Chekerov R; Churruca Galaz C; D'Incalci M; Vergote I; Berger R; Ottevanger NB; Montes A; Sessa C; et alii...

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial. in BMC medicine / BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z.

2019
AO Cuneo
AOU Città della Salute di Torino

Conte PF; Guarneri V; Griguolo G; D'Amico R; Vicini R; Balduzzi S; Foschini MP; Moretti G; Amaducci L; Bazan V; Romito S; Gambaro AR; Sarti S; Ferro A; Cagossi K; Danese S; Piacentini F; Soto Parra H; Zamagni C; Beano A; Rimanti A; Donadio M; Garrone O; Musolino A; Gebbia V; Aieta M; Giotta F; Cavanna L; Frassoldati A; et alii...

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? in OncoTargets and therapy / Onco Targets Ther. 2019 Apr 23;12:2989-2997. doi: 10.2147/OTT.S189163. eCollection 2019.

2019
AOU Città della Salute di Torino

Cazzaniga ME; Biganzoli L; Cortesi L; De Placido S; Donadio M; Fabi A; Ferro A; Generali D; Lorusso V; Milani A; Montagna E; Munzone E; Orlando L; Pizzuti L; Simoncini E; Zamagni C; Pappagallo GL;

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414.

2018
AO Cuneo
AOU Città della Salute di Torino

Vicini R; Amaducci L; Bajardi EA; Beano A; Schirone A; Lombardo L; Moretti G; Giovanardi F; Pronzato P; Russo A; Cagossi K; Rimanti A; Zamagni C; Danese S; Maltoni R; Ferro A; Musolino A; Molino A; Gebbia V; Aieta M; Giotta F; Cavanna L; Piacentini F; Garrone O; Donadio M; Brandes AA; Bisagni G; Frassoldati A; Conte P; et alii...